3rd Sep 2018 07:00
Mereo BioPharma Group plc
("Mereo" or the "Company")
Block Listing Application
London, 3 September 2018 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces that an application has been made to the London Stock Exchange for a block listing of 7,651,151 ordinary shares of £0.003 each in the Company ("Ordinary Shares").
These Ordinary Shares will be issued from time to time in order to satisfy the requirement to allot shares under the 2015 Plan and the Mereo BioPharma Group plc Share Option Plan.
It is expected that admission will become effective on 6 September 2018. The Ordinary Shares under the block listing will rank pari passu with the Company's existing Ordinary Shares.
Enquiries:
Mereo BioPharma Group plc | +44 (0)333 023 7300 |
Denise Scots-Knight, Chief Executive Officer | |
Richard Jones, Chief Financial Officer | |
Cantor Fitzgerald Europe (Nominated Adviser and Broker) | +44 (0)20 7894 7000 |
Phil Davies | |
Will Goode | |
Rick Thompson | |
RBC Capital Markets (Joint Broker) | +44 (0)20 7653 4000 |
Rupert Walford Jamil Miah | |
FTI Consulting (Public Relations Adviser) | +44 (0)20 3727 1000 |
Simon Conway | |
Brett Pollard | |
Burns McClellan (US Public Relations Advisor to Mereo Biopharma) | +01 (0) 212 213 0006 |
Lisa Burns | |
Steven Klass |
About Mereo
Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. The portfolio currently consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies: BPS-804 (setrusumab) for the treatment of osteogenesis imperfecta ("OI"); MPH-966 (alvelestat) for the treatment of severe alpha-1 antitrypsin deficiency ("AATD"); BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease, ("AECOPD"); and BGS-649 for the treatment of hypogonadotropic hypogonadism ("HH") in obese men. Each of the Company's product candidates has generated positive clinical data for Mereo's target indication or in a related indication. The Company's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. Since inception the Company has commenced large, randomized, placebo-controlled Phase 2 clinical trials for three of the product candidates and has previously announced positive top-line results from two of its clinical trials: a Phase 2 trial with BCT-197 in December 2017 and a Phase 2b dose-ranging study with BGS-649 in March 2018.
Related Shares:
MPH.L